Abstract: A lipid delivery system, a virus-like structure (VLS) vaccine constructed therefrom, and a lipid particle capable of encapsulating an mRNA molecule encoding a SARS-CoV-2-specific antigen are provided. After the lipid particle encapsulates an mRNA molecule encoding a SARS-CoV-2 antigen, a SARS-CoV-2 S1 antigen protein can be embedded on a surface of an envelope structure of the lipid under specific buffer conditions to produce a VLS vaccine with an antigen-encoding mRNA molecule encapsulated inside and an outer membrane presenting a required viral antigen protein. The vaccine has a superior specific antibody-inducing ability to a SARS-CoV-2 mRNA vaccine and a polypeptide vaccine, can maintain a long-lasting high antibody level, and can also exhibit excellent immune binding abilities for the emerging different variants.

Abstract: Described herein are immune cells comprising: a T-cell receptor (TCR) and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or components thereof (e.g., the CSR) for therapeutic treatment of cancers (e.g., solid tumor cancers).

Abstract: The present disclosure relates to the technical field of vehicle steering, and provides an electrically adjustable steering column and an electric power steering system.

Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.

Abstract: The present invention discloses an optimization method for natural gas pipeline operation under the carbon neutrality target. From the perspective of energy structure adjustment, the present invention proposes a complete low-carbon and low-consumption optimization model of long-distance natural gas transmission network, which is used for fine calculation of multi-energy carbon emissions and energy consumption in the transportation process of natural gas pipeline network; according to different energy structure backgrounds, the corresponding objective function for minimum carbon emissions is established, the optimization algorithm is adopted to solve the objective function for minimum carbon emissions and work out the optimal scheduling scheme.

Abstract: Provided herein are components (e.g., cells and soluble proteins), systems, and methods for assessing the biological activity of soluble proteins comprising an Fc domain and a CD28-binding domain (e.g., CD80 extracellular domain Fc fusion proteins).

Abstract: Described herein are immune cells comprising: a chimeric antigen receptor (CAR) that comprises (i) an extracellular target-binding domain comprising an antibody moiety; (ii) a transmembrane domain; and (iii) a primary signaling domain, and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or compositions thereof for therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers).

Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.

Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.